Compare BFS & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFS | DRUG |
|---|---|---|
| Founded | 1993 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 770.9M | 707.1M |
| IPO Year | N/A | 2020 |
| Metric | BFS | DRUG |
|---|---|---|
| Price | $32.97 | $74.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $124.00 |
| AVG Volume (30 Days) | 57.4K | ★ 82.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.14% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.07 | N/A |
| Revenue Next Year | $7.05 | N/A |
| P/E Ratio | $30.48 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.16 | $23.18 |
| 52 Week High | $36.51 | $123.75 |
| Indicator | BFS | DRUG |
|---|---|---|
| Relative Strength Index (RSI) | 46.81 | 43.15 |
| Support Level | $31.09 | $72.06 |
| Resistance Level | $35.18 | $91.00 |
| Average True Range (ATR) | 0.92 | 4.34 |
| MACD | -0.24 | -1.04 |
| Stochastic Oscillator | 42.73 | 27.48 |
Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: shopping centers, which contribute the maximum portion of total revenue; and mixed-use properties. Maximum tenants include grocery stores, discount department stores, and drug stores.
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.